AIM ImmunoTech Inc
AIM
查看詳細走勢圖
1.440USD
+0.079+5.83%
收盤 12/19, 16:00（美東）報價延遲15分鐘
3.98M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+5.83%
5天
+5.11%
1月
+8.27%
6月
-82.65%
今年開始到現在
0.00%
1年
0.00%
查看詳細走勢圖
TradingKey AIM ImmunoTech Inc股票評分
單位: USD 更新時間: 2025-12-19操作建議
AIM ImmunoTech Inc當前公司基本面數據相對穩定，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名138/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價22.00。中期看，股價處於下降通道。近一個月，市場表現一般，但技術面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
AIM ImmunoTech Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
1
分析師
買入
評級
22.000
目標均價
+1347.37%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
AIM ImmunoTech Inc亮點
亮點風險
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
業績高增長
公司營業收入穩步增長，連續3年增長20.57%
業績增長期
公司處於發展階段，最新年度總收入170.00K美元
估值高估
公司最新PE估值-0.08，處於3年歷史高位
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉，最新持倉0.00股
AIM ImmunoTech Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
AIM ImmunoTech Inc簡介
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
公司代碼AIM
公司AIM ImmunoTech Inc
CEOEquels (Thomas K)
網址https://aimimmuno.com/
常見問題
AIM ImmunoTech Inc(AIM)的當前股價是多少？
AIM ImmunoTech Inc(AIM)的當前股價是 1.440。
AIM ImmunoTech Inc 的股票代碼是什麼？
AIM ImmunoTech Inc的股票代碼是AIM。
AIM ImmunoTech Inc股票的52週最高點是多少？
AIM ImmunoTech Inc股票的52週最高點是36.000。
AIM ImmunoTech Inc股票的52週最低點是多少？
AIM ImmunoTech Inc股票的52週最低點是1.260。
AIM ImmunoTech Inc的市值是多少？
AIM ImmunoTech Inc的市值是3.98M。
AIM ImmunoTech Inc的淨利潤是多少？
AIM ImmunoTech Inc的淨利潤為-17.32M。
現在AIM ImmunoTech Inc(AIM)的股票是買入、持有還是賣出？
根據分析師評級，AIM ImmunoTech Inc(AIM)的總體評級為買入，目標價格為22.000。
AIM ImmunoTech Inc(AIM)股票的每股收益（EPS TTM）是多少
AIM ImmunoTech Inc(AIM)股票的每股收益（EPS TTM）是-17.823。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
